IN2015DN00637A - - Google Patents

Info

Publication number
IN2015DN00637A
IN2015DN00637A IN637DEN2015A IN2015DN00637A IN 2015DN00637 A IN2015DN00637 A IN 2015DN00637A IN 637DEN2015 A IN637DEN2015 A IN 637DEN2015A IN 2015DN00637 A IN2015DN00637 A IN 2015DN00637A
Authority
IN
India
Prior art keywords
granular fraction
pharmaceutically acceptable
acceptable excipient
formulations
excipient component
Prior art date
Application number
Other languages
English (en)
Inventor
Reza Fathi
Patrick Laughlin Mclean
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of IN2015DN00637A publication Critical patent/IN2015DN00637A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08Oxides; Hydroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN637DEN2015 2012-07-27 2013-07-26 IN2015DN00637A (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261676608P 2012-07-27 2012-07-27
PCT/IB2013/001640 WO2014016671A2 (en) 2012-07-27 2013-07-26 Formulations and methods of manufacturing formulations for use in colonic evacuation

Publications (1)

Publication Number Publication Date
IN2015DN00637A true IN2015DN00637A (https=) 2015-06-26

Family

ID=49997911

Family Applications (1)

Application Number Title Priority Date Filing Date
IN637DEN2015 IN2015DN00637A (https=) 2012-07-27 2013-07-26

Country Status (24)

Country Link
US (3) US10166219B2 (https=)
EP (1) EP2877163B1 (https=)
JP (1) JP6454640B2 (https=)
KR (1) KR102152873B1 (https=)
CN (2) CN108175773A (https=)
AU (1) AU2013294737B2 (https=)
BR (1) BR112015001640A2 (https=)
CA (1) CA2880282C (https=)
CY (1) CY1121852T1 (https=)
DK (1) DK2877163T3 (https=)
ES (1) ES2717282T3 (https=)
HR (1) HRP20190550T1 (https=)
HU (1) HUE043852T2 (https=)
IL (1) IL236791B (https=)
IN (1) IN2015DN00637A (https=)
MX (1) MX366707B (https=)
NZ (1) NZ704014A (https=)
PH (1) PH12015500165A1 (https=)
PL (1) PL2877163T3 (https=)
PT (1) PT2877163T (https=)
RU (1) RU2015106688A (https=)
SI (1) SI2877163T1 (https=)
TR (1) TR201904884T4 (https=)
WO (1) WO2014016671A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103338768B (zh) 2010-12-13 2019-04-19 萨利克斯药品有限公司 胃和结肠的配制剂及其制备和使用方法
HUE043852T2 (hu) * 2012-07-27 2019-09-30 Redhill Biopharma Ltd A vastagbél kiürítésére szolgáló készítmények és a készítmények elõállítási módszerei
IN2013MU02911A (https=) * 2013-09-10 2015-07-03 Cadila Healthcare Ltd
KR101420315B1 (ko) 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
CA2995798A1 (en) 2015-08-17 2017-02-23 Nipul Ghanshyambhai PATEL Liquid formulations containing picosulfate and magnesium citrate
TW201804996A (zh) * 2016-07-08 2018-02-16 輝凌責任有限公司 含有匹可硫酸鹽(picosulfate)之安定液體調配物
EP3345591A1 (en) * 2017-01-06 2018-07-11 Oystershell NV Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation
JP7340572B2 (ja) * 2021-08-20 2023-09-07 セトラスホールディングス株式会社 酸化マグネシウム錠剤

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459863A (en) * 1966-10-14 1969-08-05 Merck & Co Inc Color-stable ascorbic acid tablet
US4186025A (en) 1975-09-25 1980-01-29 Merck & Co., Inc. Aqueous polysaccharide composition
US4452779A (en) 1982-02-03 1984-06-05 Cockerill Vernon Composition and method of treating lactating mammals
DK454683D0 (da) 1983-10-03 1983-10-03 Mogens Gjerloev Tarmreguleringsmiddel til behandling af diarre hos dyr samt anvendelse heraf
WO1986005981A1 (en) 1985-04-18 1986-10-23 Borody Thomas J Treatment of non-ulcer dyspepsia with bismuth salts
US4766004A (en) 1986-12-19 1988-08-23 Warner-Lambert Company Crunchy, highly palatable, bulk-increasing, dietary fiber supplement composition
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
JP2733849B2 (ja) 1987-10-12 1998-03-30 ボロディー,ソーマス・ユリウス 胃腸障害治療のための改良された方法
US5274001A (en) 1987-12-24 1993-12-28 Borody Thomas J Orthostatic lavage solutions
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
EP0433299B1 (en) 1988-08-02 1998-05-06 Gastro Services Pty. Limited (ACN 002 994 890) Treatment of gastro-intestinal disorders
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5232699A (en) 1990-07-26 1993-08-03 The Proctor & Gamble Company Laxative compositions
DE69133348T3 (de) 1990-10-22 2011-05-12 Centre for Digestive Diseases Pty, Ltd. Behandlung von nicht-entzündlichen darmerkrankungen
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5173296A (en) 1990-11-16 1992-12-22 The Procter & Gamble Company Compositions containing psyllium
JPH06132767A (ja) 1992-10-22 1994-05-13 Rohm Co Ltd 圧電発振子
CA2156726C (en) 1993-02-26 2000-10-17 Paula Denise Davis Bisacodyl dosage form
JP2974550B2 (ja) 1993-06-01 1999-11-10 ビオフェルミン製薬株式会社 経口投与用固体組成物
EP0724441A1 (en) * 1993-10-19 1996-08-07 The Procter & Gamble Company Picosulphate dosage form
JP3850891B2 (ja) 1994-03-01 2006-11-29 ゼリア新薬工業株式会社 緩下効果を有する組成物
AUPM695294A0 (en) 1994-07-20 1994-08-11 Borody, Thomas Julius Improved combination therapy dose unit
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
RU2098100C1 (ru) 1995-10-11 1997-12-10 Максимова Ирина Сергеевна Ирригационный раствор для офтальмологических операций
AU771576B2 (en) 1995-11-03 2004-03-25 Red Hill Biopharma Ltd. Improved preparation for colonic evacuation
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
NZ333493A (en) 1995-11-03 2000-06-23 Nicolas Peter Shortis Method of evacuating a patient's colon by oral administration of an osmotic colonic evacuant in powder form
US6103268A (en) 1995-11-03 2000-08-15 Borody; Thomas Julius Administering osmotic colonic evacuant containing a picosulfate
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
PT922464E (pt) * 1996-07-12 2005-07-29 Daiichi Seiyaku Co Materiais moldados por compressao rapidamente desintegraveis e processo para a sua producao
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
US6551632B2 (en) 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AR012304A1 (es) 1997-04-01 2000-10-18 Borody Thomas J Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
US6303662B1 (en) 1997-04-18 2001-10-16 Taisho Pharmaceutical Co., Ltd. Microemulsion
AUPO665397A0 (en) 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AR017512A1 (es) 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
ZA987592B (en) * 1997-08-22 1999-02-22 Smithkline Beecham Corp Rapdily disintegrating methylcellulose tablets
JP4092748B2 (ja) 1997-09-05 2008-05-28 ニプロ株式会社 腸管洗浄液
US5843477A (en) * 1997-09-30 1998-12-01 Bayer Corporation Lubricants for use in tabletting
CA2315088A1 (en) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets
AUPP325398A0 (en) 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ES2316350T3 (es) 1999-02-26 2009-04-16 SHIONOGI & CO., LTD. Capsulas blandas masticables con propiedades mejoradas de administracion y procedimiento para producirlas.
US6858403B2 (en) 1999-05-11 2005-02-22 M-Biotech, Inc. Polymer matrix containing catalase co-immobilized with analytic enzyme that generates hydrogen peroxide
DE19930030B4 (de) 1999-06-30 2004-02-19 Meduna Arzneimittel Gmbh CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform
CN1288730A (zh) 1999-09-07 2001-03-28 麦克内尔-Ppc股份有限公司 轻泻组合物
US6774111B1 (en) 2000-03-14 2004-08-10 Abbott Laboratories Carbohydrate system and a method for providing nutrition to a diabetic
NZ522036A (en) 2000-04-19 2004-04-30 Borody Thomas J Compositions and therapies for hyperlipidaemia-associated disorders
JP2003535903A (ja) 2000-06-19 2003-12-02 ミューコプロテック・プロプライエタリー・リミテッド プロバイオティックを用いた、粘膜表面での細菌またはウイルス感染の免疫療法または治療、およびそのための組成物
AUPQ854100A0 (en) 2000-07-03 2000-07-27 Helirad Pty Ltd Methods for monitoring treatment of helicobacter infection
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
KR20030087009A (ko) 2001-02-27 2003-11-12 랜박시 래보러터리스 리미티드 세프포독심 프록세틸의 경구용 약학 조성물
CA2439209A1 (en) 2001-03-13 2002-09-19 Kellogg Company Aerated food component
US6790453B2 (en) 2001-03-14 2004-09-14 Mccormick & Company, Inc. Encapsulation compositions and process for preparing the same
US7815956B2 (en) 2001-04-27 2010-10-19 Pepsico Use of erythritol and D-tagatose in diet or reduced-calorie beverages and food products
EP2260837A1 (en) 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
CA2452577C (en) 2001-07-05 2011-04-19 Wakunaga Pharmaceutical Co., Ltd. Soft capsules
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
AUPS017702A0 (en) 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
HUE032656T2 (en) 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
US6946149B2 (en) 2002-04-30 2005-09-20 Braintree Laboratories, Inc. Salt solution for colon cleansing
JP4591742B2 (ja) 2003-01-06 2010-12-01 大正製薬株式会社 ジオクチルソジウムスルホサクシネート配合製剤およびその製造方法
AU2003900553A0 (en) 2003-02-10 2003-02-20 Borody, Thomas Julius Novel Improved Method for Detection of Dientamoeba fragilis and other Parasites
RU2005134364A (ru) 2003-04-08 2006-06-10 Проджиникс Фармасьютикалз, Инк. (Us) Комбинированное лечение запора
WO2004100857A2 (en) 2003-05-07 2004-11-25 Akina, Inc. Highly plastic granules for making fast melting tablets
US20040265378A1 (en) 2003-06-25 2004-12-30 Yingxu Peng Method and compositions for producing granules containing high concentrations of biologically active substances
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
JP2005255595A (ja) 2004-03-10 2005-09-22 Taisho Pharmaceut Co Ltd ジオクチルソジウムスルホサクシネート配合錠剤
JP2005272401A (ja) 2004-03-25 2005-10-06 Tendou Seiyaku Kk チュアブル錠
EP1737537A1 (en) 2004-04-13 2007-01-03 Boehringer Ingelheim International GmbH Use of simethicone in constipated patients
KR100749229B1 (ko) 2005-04-29 2007-08-13 (주)아모레퍼시픽 당 및 당알콜을 함유하는 변비개선용 조성물
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
DE102006033014A1 (de) 2005-09-13 2007-04-05 Volkswagen Ag Eingabevorrichtung für ein Kraftfahrzeug
WO2007057924A1 (en) 2005-11-21 2007-05-24 Panacea Biotec Ltd Laxative composition on the basis of triphala
CA2635313C (en) 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
JP5006567B2 (ja) 2006-04-14 2012-08-22 花王株式会社 口腔用固形製剤
US20090252787A1 (en) 2006-07-28 2009-10-08 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008027442A2 (en) 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
US20080132646A1 (en) 2006-12-04 2008-06-05 Delson Jayme Trindade Acrylic polyol coating composition
WO2008141368A1 (en) 2007-05-17 2008-11-27 David Lubowski Combination laxative compositions comprising a colonic stimulant and a bulking laxative
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
KR20160083132A (ko) 2007-06-06 2016-07-11 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
JP2010529073A (ja) 2007-06-06 2010-08-26 ビーエーエスエフ ソシエタス・ヨーロピア チュアブル錠及びトローチ剤製造のための医薬製剤
CN103691530A (zh) 2007-07-27 2014-04-02 卡吉尔公司 多元醇的微粉化
EP2196221A4 (en) 2007-09-27 2011-12-28 Mitsubishi Tanabe Pharma Corp QUICKLY CRUMPING SOLID PREPARATION
BRPI0817927A2 (pt) 2007-10-01 2015-04-07 Lesvi Laboratorios Sl Comprimidos orodispersiveis
NZ583899A (en) * 2007-10-12 2011-12-22 Ferring Int Ct Sa Process for the manufacure of a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising granules obtained by such process and intermediate
CN101406457A (zh) * 2007-10-12 2009-04-15 辉凌国际制药(瑞士)有限公司 制备药物产品的方法
EP2214635A1 (en) 2007-10-19 2010-08-11 Purdue Research Foundation Solid formulations of crystalline compounds
JP5258268B2 (ja) 2007-11-19 2013-08-07 フロイント産業株式会社 球形粒の製造方法
US20090155363A1 (en) 2007-12-14 2009-06-18 Todd Maibach Methods for oral administration of active drugs
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
EP2233129B1 (en) 2007-12-28 2014-05-07 Sawai Pharmaceutical Co., Ltd. Oral cavity disintegrating tablet and method of producing the same
US20090258090A1 (en) 2008-04-11 2009-10-15 Braintree Laboratories, Inc. Colon cleansing solution
US20100178413A1 (en) 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
WO2010138439A1 (en) 2009-05-28 2010-12-02 Aptapharma, Inc. Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations
JP2011019046A (ja) 2009-07-08 2011-01-27 Nec Commun Syst Ltd 通信制御装置、通信制御方法、プログラム、及び記録媒体
JP5674667B2 (ja) * 2009-08-11 2015-02-25 富士化学工業株式会社 崩壊性粒子組成物及び口腔内速崩壊錠
JP5674666B2 (ja) * 2009-08-11 2015-02-25 富士化学工業株式会社 崩壊性粒子組成物及び口腔内速崩壊錠
JP5663238B2 (ja) 2009-08-31 2015-02-04 ライオン株式会社 内服固形製剤及びその製造方法
JP2011157348A (ja) * 2010-01-05 2011-08-18 Fuji Chem Ind Co Ltd 崩壊性高強度球状粒子組成物
JP5711520B2 (ja) 2010-01-06 2015-04-30 三洋化成工業株式会社 外用組成物
US20110218216A1 (en) 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
JP2012079118A (ja) 2010-10-01 2012-04-19 Toyota Motor Corp 走行支援装置及び方法
CN103338768B (zh) * 2010-12-13 2019-04-19 萨利克斯药品有限公司 胃和结肠的配制剂及其制备和使用方法
MX352891B (es) 2011-10-27 2017-12-13 Salix Pharmaceuticals Inc Purgantes electroliticos.
HUE043852T2 (hu) 2012-07-27 2019-09-30 Redhill Biopharma Ltd A vastagbél kiürítésére szolgáló készítmények és a készítmények elõállítási módszerei
CN104936581A (zh) 2012-08-29 2015-09-23 萨利克斯药品有限公司 用于治疗便秘和相关胃肠道疾病和疾病状态的泻药组合物和方法

Also Published As

Publication number Publication date
US10166219B2 (en) 2019-01-01
CN108175773A (zh) 2018-06-19
JP6454640B2 (ja) 2019-01-16
EP2877163B1 (en) 2019-03-20
AU2013294737A1 (en) 2015-02-05
PH12015500165A1 (en) 2015-03-16
AU2013294737B2 (en) 2018-05-24
US20200222375A1 (en) 2020-07-16
IL236791B (en) 2020-08-31
KR102152873B1 (ko) 2020-09-08
US20150272937A1 (en) 2015-10-01
SI2877163T1 (sl) 2019-06-28
PT2877163T (pt) 2019-05-24
TR201904884T4 (tr) 2019-05-21
HUE043852T2 (hu) 2019-09-30
WO2014016671A3 (en) 2014-03-13
US10493065B2 (en) 2019-12-03
RU2015106688A (ru) 2016-09-20
EP2877163A2 (en) 2015-06-03
JP2015522652A (ja) 2015-08-06
DK2877163T3 (en) 2019-04-15
NZ704014A (en) 2017-10-27
KR20150044027A (ko) 2015-04-23
HRP20190550T1 (hr) 2019-05-31
HK1212596A1 (zh) 2016-06-17
PL2877163T3 (pl) 2019-08-30
US20190240205A1 (en) 2019-08-08
BR112015001640A2 (pt) 2017-07-04
MX2015000971A (es) 2015-07-14
ES2717282T3 (es) 2019-06-20
IL236791A0 (en) 2015-03-31
CN104797244B (zh) 2018-03-09
EP2877163A4 (en) 2015-12-09
MX366707B (es) 2019-07-22
CN104797244A (zh) 2015-07-22
CY1121852T1 (el) 2020-07-31
CA2880282C (en) 2020-09-01
CA2880282A1 (en) 2014-01-30
WO2014016671A2 (en) 2014-01-30
US11058671B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
IN2015DN00637A (https=)
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
MX2015000114A (es) Composiciones farmaceuticas disuasivas de abuso de liberacion prolongada.
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
IN2015DN03984A (https=)
HK1218621A1 (zh) 用於治疗慢性炎症和炎性疾病的组合物及方法
PL3003285T3 (pl) Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
PH12015501982A1 (en) Pharmaceutical compositions comprising everolimus
ZA201508454B (en) Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component
CL2014003503A1 (es) Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano.
EP3250214A4 (en) High surface-area lyophilized compositions comprising arsenic for oral administration in patients
PH12015501783B1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
TN2015000267A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
MY197454A (en) Non-enteric pharmaceutical composition comprising crofelemer
UY33103A (es) Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
WO2014013090A3 (en) Formulation comprising amorphous fingolimod
IN2014DN07895A (https=)
BR112013000870A2 (pt) forma de dosagem farmacêutica oral em comprimidos
IN2013MU02015A (https=)
MX2016004445A (es) Formulacion en polvo de triflusal estable para la administracion oral y metodo de preparacion de esta.
PH12015502015A1 (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations
CA2864049A1 (en) Use of beta-nerve growth factor for inducing ovulation in mammals
ZA201308924B (en) Pharmaceutical composition comprising an antiviral agent and method for the preparation thereof